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Keratinocyte proliferationA signiﬁcant involvement of nitric oxide (NO) in the process of keratinocyte proliferation is reported with
many divergences. To determine the involvement of NO in the hyperproliferative process of epidermis in
vivo, non-selective inhibitor (NG-nitro-L-arginine-methyl ester.HCl: L-NAME) and selective inhibitors for
inducible NO synthase (iNOS) and neuronal NO synthase (nNOS) (Aminoguanidine: AG and 7-Nitroindazole:
7-NI, respectively) and a NO-donor (Sodium nitroprusside: SNP) were topically applied twice a day in mice
ear treated with multiple applications of croton oil. L-NAME and 7-NI treatments decreased and SNP
increased ear edema formation. However, ear weight was reduced in groups that received L-NAME and 7-NI,
while the AG and SNP groups presented an increment. The histological evaluation of epidermis thickness
showed that all NOS inhibitors were able to prevent the increase in epidermis width caused by croton oil,
while SNP contributed to enlargement. The same results were observed in the PCNA staining, where
treatments with NOS inhibitors caused a reduction in the number of cells in the epidermis, while SNP caused
an enhancement. 7-NI treatment reduced polymorphonuclear and mononuclear leukocytes migration when
compared to the control group. The AG application increased the migration of polymorphonuclear and
mononuclear cells, while the SNP enhanced only the polymorphonuclear cells. Therefore, in the skin NO
produced by nNOS is involved in the control of keratinocyte hyperproliferation, with the contribution of
iNOS. In the animal model of cutaneous chronic inﬂammation by croton oil, NO is involved in the exudation
and leukocyte migration, with participation of all three enzymes.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The skin comprises approximately 2 m2 of the human body
surface and represents the largest organ in the body, providing the
main physical barrier against the environment. Keratinocytes are the
predominant cell type in the epidermis (covering 90% of the cells)
and are responsible for the maintenance of the keratin barrier. These
cells are also biochemically active, supporting other cellular compo-
nents of the epithelial microenvironment (Spellberg, 2000). They
form a mechanical barrier, which also functions as an immunological
defence against pathogens and noxious stimuli from the environ-
ment, and prevent water loss by the organism. The epidermis consists
of several layers of keratinocytes: the basal layer directly facing the
basal membrane, spinous layer, granular layer, and the outermosto Paraná, Setor de Ciências
Hoffman dos Santos, s/n, CEP:
+55 41 3361 1539; fax: +55
evier OA license.stratum corneum. The epidermis is a dynamic structure whose
integrity depends on a constant production of new cells in the basal
layer and their outward migration and differentiation (Gniadecki,
1998).
Nitric oxide (NO) is an important signalling molecule involved in
many physiological and pathological processes. NO is synthesised by
three types of NO synthases (NOS), neuronal NOS (nNOS), endothe-
lial NOS (eNOS), and inducible NOS (iNOS), all of which are expressed
in the skin (Bruch-Gerharz et al., 1998; Cals-Grierson and Ormerod,
2004). In the skin, NO has been implicated in numerous homeostatic
functions, including keratinocyte proliferation, melanogenesis, an-
giogenesis, wound healing, collagen synthesis, blood ﬂow, vascular
tone regulation, neurotransmission, platelet aggregation, warming
and other homeostatic mechanisms (Boissel et al., 2004; Brown et al.,
2006; Frank et al., 2000; Mayer and Hemmens, 1997; Romero-Graillet
et al., 1997). However, it also mediates pathological conditions, such
as immune-mediated skin diseases, and other inﬂammatory diseases,
including sunburn, psoriasis, toxic epidermal necrosis and cutaneous
lupus erythematosus (Bruch-Gerharz et al., 2003; Lerner et al., 2000;
Paunel et al., 2005).
2 D.A.G.B. Mendes et al. / European Journal of Pharmacology 687 (2012) 1–8In vitro studies demonstrated that low concentrations of NO
donors stimulated the proliferation of primary keratinocytes, where-
as high concentrations caused cytostatic effects (Bruch-Gerharz et al.,
1998; Krischel et al., 1998; Rossi et al., 2000). Although the addition of
a NO donor to the culture medium apparently did not affect the
morphology of differentiating epidermal keratinocytes, it generated
dramatic effects in dermal ﬁbroblasts as they underwent apoptosis
within 6 days. On the other hand, inhibition of endogenous NO
production by addition of the NOS inhibitor NG-nitro-L-arginine-
methyl ester.HCl (L-NAME) had no effect on cultured ﬁbroblasts, but
unexpectedly induced apoptosis in differentiating keratinocytes after
5 days (Gallala et al., 2004).
Several reports have focused on the potential of NO to inﬂuence the
proliferation and differentiation cascade in a number of mammalian
cells, but in the case of keratinocytes, all studies are conducted only in
cell culture. For a long time it was assumed that NO presented a non-
speciﬁc role in defence. However, it is clear that NO plays a key role in
the skin response to external stimuli such as heat, ultraviolet (UV) light,
response to infection, inﬂammation, wound healing, and possibly
underlying certain pathological conditions. Thus, the aim of this study
was to investigate the role of NO upon the hyperproliferation of
epidermal keratinocytes by analysing NOS inhibitors and NO donor
effects in an animal model of chronic skin inﬂammation caused by
croton oil.2. Material and methods
2.1. Animals
All procedures were carried out on adult male Swiss mice
weighing 25–35 g. Animals were randomly allocated to one of seven
groups (n=10 per group). Food and water were supplied ad libitum
and the animals were kept in a 12 h light/dark cycle and in a
temperature-controlled room (22±2 °C). All animal procedures were
performed after approval of the protocol by the Institutional Ethics0 1 2 3 4 5 6 7 8 9 10
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Fig. 1. Effect of (A) L-NAME (10 μmol/ear), (B) AG (10 μmol/ear), (C) 7-NI (10 μmol/ear), (D
on ear edema induced by multiple application of croton oil (0.4 mg/ear). Treatments were in
thickness of the basal right ear and over the following 9 days after induction of edema. The
between the groups was veriﬁed by analysis of variance (ANOVA) followed by New
dexamethasone to the control group. *P b0.05 was indicative of signiﬁcance when compareCommittee of Federal University of Paraná and were carried out in
accordance with current guidelines for the care of laboratory animals.
2.2. Chemicals
Croton oil, Dexamethasone, Tetramethylbenzidine (TMB), 4-
Nitrophenyl N-acetyl-β-D-glucosaminide (NAG), Sodium citrate dehy-
drate, Sodium nitroprusside dehydrate (SNP), Glycine anhydride,
Hexadecyltrimethylammonium Bromide (HTAB) and Albumin from
serum bovine (BSA) were purchased from Sigma Chemical Co (St. Louis
MO); DAB substrate Kit was purchased from BD Biosciences (San
Diego, CA, USA); Acetone, Aminoguanidine (AG), Formaldehyde,
Glacial acetic acid, Parafﬁn, and Phosphate-buffered saline (PBS) were
purchased from Merck Biosciences (Germany); Sodium acetate
Anhydrous P.A., Hydrogen peroxide, Absolute ethanol, Eosin, Hema-
toxylin and Xylene were purchased from Vetec (Rio de Janeiro, Brazil);
NG-nitro-L-arginine-methyl ester.HCl (L-NAME) was purchased from
Alexis Biochemicals–Enzo Life Sciences International, Inc. (Plymouth
Meeting, PA, USA); 7-Nitroindazole (7-NI) was purchased from A.G.
Scientiﬁc, Biochemical Manufacturer (San Diego, CA, USA); Antibody
anti-PCNA (C-20) goat polyclonal IgG and Antibody donkey anti-goat
IgG HRP were purchased from Santa Cruz Biotechnology, Inc. (CA,
USA).
2.3. Animal protocol
The chronic inﬂammatory process was induced by multiple applica-
tion of croton oil (0.4 mg/ear) for nine days on alternate days. The mice
were topically treated with the NG-nitro-L-arginine-methyl ester.HCl
(L-NAME) (10 μmol/ear), Aminoguanidine (AG) (10 μmol/ear), Sodium
nitroprusside dehydrate (SNP) (2.5 μmol/ear), 7-Nitroindazole (7-NI)
(10 μmol/ear) or Dexamethasone (0.1 mg/ear). The animals were
treated twice daily from the ﬁfth day and the edema was expressed as
the increase in ear thickness (mm), assessed daily using a digital
micrometer (Great, MT-04513). Tominimise variations in the technique,0 1 2 3 4 5 6 7 8 9 10
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points represent the mean and vertical bars the S.E.M. of 5–10 animals. The correlation
man–Keuls post-hoc test. #Pb0.05 was indicative of signiﬁcance when compared
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Fig. 2. Effect of L-NAME (10 μmol/ear), AG (10 μmol/ear), 7-NI (10 μmol/ear), SNP
(2.5 μmol/ear), dexamethasone (0.1 mg/ear) and vehicle (water–acetone, 5% v/v) on
ear weight in 9th day after multiple applications of croton oil (0.4 mg/ear). All data
shown are mean±S.E.M. of 5–10 animals. The correlation between the groups was
veriﬁed by analysis of variance (ANOVA) followed by Newman–Keuls post-hoc test.
#Pb0.05 was indicative of signiﬁcance when compared to the vehicle group and
*Pb0.05 was indicative of signiﬁcance when compared to the control group.
3D.A.G.B. Mendes et al. / European Journal of Pharmacology 687 (2012) 1–8the experiments were always performed by a single investigator. The
croton oil, dexamethasone and 7-NI were dissolved in 20 μl of acetone
while L-NAME, AG and SNP were dissolved in 20 μl of water-acetone
(5% v/v) applied in the right ear of each mice.
On the last day of the experiment the animals were killed by
cervical dislocation and 6 mm circles of ear tissue were collected,
weighted and submitted to the assessment of the histological and
immunohistochemistry (PCNA) analysis (n=5 per group) and
myeloperoxidase (MPO) and N-acetyl-β-D-glucosaminidase (NAG)
enzymatic activity (n=5 per group).
2.4. Histological assessment of epidermis
Ear samples collected from mice were ﬁxed in solution ALFAC
(ethanol 80%, formalin 40% and glacial acetic acid). The ears were then
dehydrated, embedded in parafﬁn and sectioned into slices of 5 μm.
Slices were hydrated in xylene and a descending sequence of ethanol,
then stained with hematoxylin and eosin. To evaluate the epidermis
thickness, slices were photographed in increments of 200× and the
photographs analysed with the ImageJ software version 1.41 (National
Institute of Health, USA). Epidermis thicknesses are expressed in μm.
2.5. Immunohistochemical assessment of proliferation cell
Sections (5 μm) of ALFAC-ﬁxed, parafﬁn-embedded tissue were
cut onto silanised glass slides and deparafﬁnised two times with
xylene for 10 min each and rehydrated through a graded alcohol bath.
To block radical aldehyde, each section was treated with glycine
(0.1 M) for 2 min and to block endogenous peroxidase it was treated
with 3% hydrogen peroxide in methanol for 10 min. Slices were
treated with phosphate-buffered saline (PBS) containing 1% bovine
serum albumin (BSA) for 30 min to diminish non-speciﬁc staining.
For the detection of Proliferating Cell Nuclear Antigen (PCNA), slides
were incubated with 1:100 dilutions of a polyclonal anti-PCNA
antibody (Santa Cruz Biotechnology, Inc, USA) in PBS/BSA 1% at
room temperature in a moist chamber for 2 h, after this time they
were washed with PBS/BSA 1%. Subsequently, the sections were
incubated using secondary antibody IgG HRP (Santa Cruz Biotechnology,
Inc, USA) diluted 1:100 in PBS/BSA 1% at room temperature in a moist
chamber for 1 h. The peroxidase-binding sites were detected by staining
with Kit substrate of DAB and incubated for 15 min. Between all steps thesections were washed twice in PBS. Finally, the slides were dehydrated
and mounted.
2.6. Myeloperoxidase enzymatic activity assay
To assess the enzyme activity, the methodology used was ﬁrstly
described by (Bradley et al., 1982) and modiﬁed by (De Young et al.,
1989). The biopsies (6 mm circles of tissue) were added in 0.75 ml of
80 mM PBS pH 5.4 containing 0.5% of HTBA and homogenised (45 s at
0 °C) in a motor-driven homogeniser. The homogenate was decanted
into microtubes and added to 0.75 ml of buffer previously described.
The samples (1.5 ml) were placed in microfuge tubes and centrifuged
at 11.200 ×g at 4 °C for 20 min. Triplicates of 30 μl of the supernatant
were placed on a 96-well plate, to which 200 μl of a mixture
containing 100 μl of 80 mM PBS pH 5.4, 85 μl of 0.22 M PBS pH 5.4
and 15 μl of 0.017% hydrogen peroxide into each well was subse-
quently added. The addition of 20 μl of 18.4 mM TMB in dimethyl-
formamide promoted the beginning of the reaction. The plate was
then incubated at 37 °C for 3 min and the reaction stopped by
addition of 30 μl of 1.46 M sodium acetate, pH 3.0. The enzymatic
activity was determined colorimetrically using a plate reader (EL808;
BioTech Instruments, INC) set to measure absorbance at 630 nm and
expressed as OD/Biopsy.
2.7. N-acetyl-β-D-glucosaminidase enzymatic activity assay
For the NAG activity, triplicates of 25 μl of supernatant, previously
described in MPO activity, were placed on a 96-well plate and
subsequently 100 μl of 50 mM citrate buffer pH 4.5 was added. The
reactionwas initiated by the addition of 25 μl of 2.24 mM4-Nitrophenyl
N-acetyl-β-D-glucosaminide. The plate was incubated at 37 °C for 1 h
and the reaction was stopped by addition of 30 μl of 200 nM glycine
buffer pH 10.4. The enzymatic activity was determined colorimetrically
using a plate reader (EL808; BioTech Instruments, INC) set to measure
absorbance at 405 nm and expressed as OD/Biopsy.
2.8. Statistic analysis
The results are presented as mean±S.E.M. The statistical signif-
icance between the groups was assessed by means of one-way
analysis of variance (ANOVA) followed by post-hoc Newman–Keuls
test. The accepted level of signiﬁcance for the tests was Pb0.05. All
tests were carried out using the statistical software GraphPad Prism
version 3.03, San Diego California, USA.
3. Results
3.1. Mouse ear edema induced by croton oil
The multiple applications of croton oil (0.4 mg/ear, topical)
induced formation of ear edema that starts at 24 h after the ﬁrst
dose and increases with days of treatment, reaching its maximum on
day 5, when compared to vehicle group (acetone). All treatments
(twice a day, 12 h/12 h, topical) were performed from the 5th until
the 9th day of the experiment. Application of dexamethasone
(0.1 mg/ear) was able to reduce the edema during throughout the
treatment period, starting on the 1st day of treatment when
compared to the control group (Fig. 1). Similarly, the L-NAME group
(10 μmol/ear) and 7-NI group (iNOS inhibitor, 10 μmol/ear) showed a
reduction in the edema response during the 5 days of treatment when
compared to the control group (Fig. 1A and C, respectively). Speciﬁc
iNOS inhibitor tested (AG 10 μmol/ear), when topically applied for
5 days, was not able to cause any change in the edema produced by
croton oil multiple applications (Fig. 1B). However, the use of NO donor
SNP (2.5 μmol/ear) caused a signiﬁcant increase in the croton oil-
Fig. 3. Histological representative pictures of transverse slices from mice ears stained with hematoxylin–eosin (increase of 200×, scale of 500 μm) collected after the multiple
application of croton oil (0.4 mg/ear). Groups: naive (without treatment), vehicle (water–acetone, 5% v/v), control, L-NAME (10 μmol/ear), AG (10 μmol/ear), 7-NI (10 μmol/ear),
SNP (2.5 μmol/ear) and dexamethasone (0.1 mg/ear). Treatments were initiated on the ﬁfth day of the experiment.
4 D.A.G.B. Mendes et al. / European Journal of Pharmacology 687 (2012) 1–8induced ear edema starting on the 3rd day of treatment in comparison
to the control (Fig. 1D).
At the end (9th day of treatment) repeated applications of croton
oil promoted a signiﬁcant increase in ear weight of the control group
(24.3±1.4 mg) when compared to naive (8.3±0.2 mg) and vehicle
(10.8±0.3 mg) groups. There was a weight reduction of 16.9±4.8%,
44.3±4.6% and 43.8±2.0% in the groups L-NAME, 7-NI and
dexamethasone, respectively. On the other hand in groups treated
with AG and SNP, there were increases of 24.9±5.7% and 22.0±9.2%,
respectively, in ear weight when compared to the control group
(Fig. 2).3.2. Histological assessment of epidermis
Ear samples (6 mm circles of tissue) submitted to multiple
applications of croton oil were used to evaluate cellular hyperprolifera-
tion of epidermis. Croton oil promoted an increase in epidermis
thickness in the control group (133.8±8.0 μm) when compared to
naive (16.8±0.5 μm) and vehicle (26.2±1.3 μm) groups. All inhibitors
of NOS tested were able to block this enhancement in epidermis width
in 28.2±5.3% (L-NAME), 20.7±5.3% (AG) and 42.0±3.1% (7-NI), as
well as dexamethasone (53.5±3.5%). However, when NO donor SNP
was used, it promoted an increase of 35.6±5.7% in the epidermis
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Fig. 4. Effect of L-NAME (10 μmol/ear), AG (10 μmol/ear), 7-NI (10 μmol/ear), SNP
(2.5 μmol/ear), dexamethasone (0.1 mg/ear) and vehicle (water–acetone, 5% v/v) on
epidermis thickness in the 9th day after multiple applications of croton oil (0.4 mg/
ear). Treatments were initiated on the ﬁfth day of the experiment. All data shown are
mean±S.E.M. of 12–24 slices stained with hematoxylin–eosin as described previously.
The correlation between the groups was veriﬁed by analysis of variance (ANOVA)
followed by Newman–Keuls post-hoc test. #Pb0.05 was indicative of signiﬁcance when
compared to the vehicle group and *Pb0.05 was indicative of signiﬁcance when
compared to the control group.
5D.A.G.B. Mendes et al. / European Journal of Pharmacology 687 (2012) 1–8thickness when compared to the control group (Fig. 4). Representative
photos from the histological changes of ear tissues aftermultiple topical
applications of croton oil and treatments are presented in Fig. 3.
3.3. Immunohistochemical staining of cell proliferation
Ear tissues blocked in parafﬁn were used to assess the number of
cells in proliferation through immunolabelling with anti-PCNA antibody.
Multiple applications of croton oil promoted an increase in the number
of proliferating cells in the ear skin of the control group (87.1±6.8 cells/
ﬁeld) when compared with naive (17.8±1.7 cells/ ﬁeld) and vehicle
(44.3±3.7 cells/ﬁeld) groups (Fig. 5). Animals topically treated with
L-NAME, AG, 7-NI and dexamethasone presented a reduction in the
number of cells in proliferation (57.3±3.9, 73.3±2.7, 26.0±0.9 and
37.0±1.8 cells/ﬁeld, respectively), while in the SNP group it was
ampliﬁed (100.8±6.7 cell/ﬁeld) when compared to the control group
(Fig. 6). Fig. 5 shows representative photos of immunohistochemical
changes in the cell proliferation pattern in ear tissues after multiple
applications of croton oil and respective topical treatments.
3.4. Myeloperoxidase enzymatic activity assay
Myeloperoxidase is a polymorphonuclear leukocyte marker and
the determination of its activity indicates leukocyte inﬁltration. As
expected, the repeated treatment with croton oil in the ear promoted
an increase of myeloperoxidase activity in the control group, when
compared to naive and vehicle groups (Fig. 7A). In the AG and SNP-
treated ears, the myeloperoxidase activity was further increased in
52.8±23.9% and 74.4±47.9% respectively, while in 7-NI and dexa-
methasone groups it was reduced in 39.9±10.8% and 47.0±3.4%
respectively, in comparison to control values. The other treatment with
L-NAME was not able to cause any modiﬁcation in the myeloperox-
idase activity when compared to the control group (Fig. 7A).
3.5. N-acetyl-β-D-glucosaminidase enzymatic activity assay
NAG enzymatic activity is used as an indicator of the presence of
mononuclear leukocytes in the tissue. The skin inﬂammation induced
by multiple treatments with croton oil promoted an increase of NAG
activity in the tissue of control mice when compared with naive andvehicle (Fig. 7B). Ears treated with 7-NI or dexamethasone showed a
decrease in NAG activity of 14.6±6.1% and 34.4±7.2%, respectively
in comparison to control results. However, the topical application of
AG increased NAG activity by 16.35±6.3% NAG activity induced by
repeated skin treatment with croton oil. The other groups (SNP and
L-NAME) showed no modiﬁcation in the NAG activity when compared
to the control group (Fig. 7B).
4. Discussion
The process of keratinocytes hyperproliferation with abnormal
differentiation that leads to a defective barrier formation, aberrant or
exaggerated responses to growth factors, vascular changes, and dermal
inﬂammatory cell migration are characteristics of chronic inﬂammatory
cutaneous diseases, such as psoriasis, allergic inﬂammatory diseases,
chronic wounds, among others (Gniadecki, 1998). Many studies have
been conducted in order to understand these diseases and many of
them reported a signiﬁcant involvement of NO in these processes;
however, only a few tried to show the involvement of NO in the control
of hyperproliferative epidermal process with controversies.
In the present study we demonstrated by an in vivomodel that NO
has a relevant role in the regulation of hyperproliferative keratinocytes
of the epidermis in chronic inﬂammatory disorders. Therefore we used
the model of multiple applications of croton oil to the ear which causes
a skin inﬂammatory and hyperproliferative process in the epidermis.
The active constituent of croton oil is the 12-O-tetradecanoylphorbol-
13-acetate (TPA), a well-characterised protein kinase C activator and
tumour promoter. Topical application of TPA is a valid model to screen
for compounds with an anti-inﬂammatory potentiality. TPA induces
oxidative stress, cutaneous inﬂammation and epidermal hyperplasia due
to enhanced keratinocyte proliferation, transforming growth factor-β1
(TGF-β1) and tumour necrosis factor-α (TNFα) production and the
formation of LTB4 with a resultant increase in vascular permeability and
neutrophil inﬂux (Jang and Pezzuto, 1998;Murakawa et al., 2006). In our
experiment, treatment with a non-selective inhibitor of NOS (L-NAME)
and selective nNOS inhibitor (7-NI) promoted a reduction in formation
of edemaandweight ofmice ears,while the donor of NO (SNP) increased
the ear thickness and weight. This effect of NO is probably due to its
vasodilator role. It is clearly understood that this effect is involved in a
number of inﬂammatory reactions of the skin causing enhanced vascular
permeability, edema, erythema and enhanced cell inﬁltration via
increasing local blood ﬂow in skin microcirculation (Rhodes et al.,
2001). However, treatment with the selective inhibitors for iNOS (AG)
did not alter the edema values, suggesting that nNOS and eNOS are
probably the NO producers in the edema event. Our results are in
accordance with Orita et al. (2011) who showed the involvement of NO
in other skin inﬂammatory processes.
Keratinocytes in the epidermis are formed continuously in the
proliferative basal layer and undergo a tightly regulated process of
differentiation as they progress upwards and become part of the
corniﬁed epithelium. This maturation process consists essentially of
keratinisation, morphological and metabolic changes and loss of
nucleus (Cals-Grierson and Ormerod, 2004). Data from our study
show a signiﬁcant reduction in epidermis thickness of animals treated
with inhibitors of NOS (L-NAME, AG and 7-NI), and an increase in
thickness of the epidermis layer in animals treated with NO donor
(SNP), visibly observed on the board with samples of representative
histological sections examined (Fig. 3). These results strongly suggest
that iNOS and nNOS might be responsible for NO-induced hyperproli-
feration of epidermis.
In order to conﬁrm the changes in the epidermis thickness by NO,
immunolabelling for PCNA was used, making possible the quantiﬁ-
cation of keratinocytes in the proliferation process in the epidermis
layer. The number of proliferative cells in skin treated with L-NAME,
AG and 7-NI was lower when compared to the control group, while
the group treated with SNP showed a larger amount of cells in
Fig. 5. PCNA immunohistochemical representative pictures of transverse slices from mice ears (increase of 400×, scale of 250 μm) collected on day 9 after the multiple applications
of croton oil (0.4 mg/ear). Groups: naive (without treatment), vehicle (water–acetone, 5% v/v), control, L-NAME (10 μmol/ear), AG (10 μmol/ear), 7-NI (10 μmol/ear), SNP
(2.5 μmol/ear) and dexamethasone (0.1 mg/ear). Treatments were initiated on the ﬁfth day of the experiment.
6 D.A.G.B. Mendes et al. / European Journal of Pharmacology 687 (2012) 1–8proliferation. All three NOS isoforms are expressed in the skin: the
calcium-dependent neuronal and endothelial NOS (also called NOS I
and III) produces low levels of NO, generally for homeostatic functions,
while the inducible NOS (iNOS, or NOS II) generates much higher levels
of NO in a calcium-independentmanner, and has been considered to be
involved in inﬂammatory and pathological conditions (Alderton et al.,
2001; McDonald and Murad, 1996; Michel and Feron, 1997). In a
previous study by Ikeyama et al. (2007), the activation of nNOS in the
barrier disruption was investigated, observing that the NO level
increased in the epidermis. They suggested that increasing NO-induced
generation of cGMP leads to release of calcium from the internal store,
increasing the intracellular calcium level in epidermal keratinocytes and
delaying the barrier repair. This way, if this cascade is blocked, forexample, by inhibition of NO synthesis or guanylyl cyclase, barrier
recovery is accelerated (Ikeyama et al., 2007). In the present study the
results are in accordance with this, since L-NAME and 7-NI treatments
signiﬁcantly reduced the process of hyperproliferative epidermis in vivo.
Furthermore, we found that treatment with AG was also able to inhibit
the increased proliferation of keratinocytes. We suggest that nNOS is the
main enzyme in the NO production in the epidermal hyperproliferation
process, with relevant contribution of iNOS.
Several studies have demonstrated that the mechanism of NO
involved in the skin inﬂammatory process is based on its interaction
with nuclear factor-kappa B (NF-κB). SNP topically applied into the
dorsal skin of mice caused NF-κB activation through degradation of
IκBα, and topical application of PDTC, a known inhibitor of NF-κB,
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Fig. 6. Immunohistochemical assessment of cell proliferation. Effect of L-NAME
(10 μmol/ear), AG (10 μmol/ear), 7-NI (10 μmol/ear), SNP (2.5 μmol/ear), dexameth-
asone (0.1 mg/ear) and vehicle (water–acetone, 5% v/v) on immunohistochemical
staining cell proliferation in the 9th day after by multiple applications of croton oil
(0.4 mg/ear). Treatments were initiated on the ﬁfth day of the experiment. All data
shown are mean±S.E.M. of cell number evaluated 9–21 slices marked with anti-PCNA
antibody as described previously. The correlation between the groups was veriﬁed by
analysis of variance (ANOVA) followed by Newman–Keuls post-hoc test. #Pb0.05 was
indicative of signiﬁcance when compared to the vehicle group and *Pb0.05 was
indicative of signiﬁcance when compared to the control group.
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Fig. 7. Effect of L-NAME (10 μmol/ear), AG (10 μmol/ear), 7-NI (10 μmol/ear), SNP
(2.5 μmol/ear), dexamethasone (0.1 mg/ear) and vehicle (water-acetone, 5% v/v)
topically applied on (A) myeloperoxidase and (B) N-acetyl-β-D-glucosaminidase (NAG)
activity in supernatants croton oil-treated ear. Ear enzymatic activities were measured at
9th day after multiple treatment with croton oil. All data shown are mean±S.E.M. of 3–6
animals. The correlation between the groupswas veriﬁed by analysis of variance (ANOVA)
followed by Newman–Keuls post-hoc test. #Pb0.05 was indicative of signiﬁcance when
compared to the vehicle group and *Pb0.05was indicative of signiﬁcancewhen compared
to the control group.
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NF-κB, causing a reduction in COX-2 protein expression in mouse skin
(Surh et al., 2001). Finally, Chun and collaborators described that two
different NF-κB inhibitors (PDTC and TPCK) suppressed COX-2
expression induced by SNP in mouse skin. They also conﬁrmed the
inhibitory effect of SN50, a cell permeable inhibitory peptide of NF-κB
translocation, on COX-2 expression in keratinocytes, suggesting that
the NO could induce COX-2 expression in mouse skin through NF-kB
activation (Chun et al., 2004). Medeiros et al. (2009) showed that
iNOS knockout mice have a remarkable effect on the inﬂammatory
cascade, as indicated by the decrease in the oedematogenic response
and in the number of inﬁltrating inﬂammatory cells in response to
TPA in the mouse ear. The inﬂammatory effects mediated by iNOS
seem to be associated with its ability to stimulate the activation of
ERK and p38 MAPK, which in turn controls the transcriptional factors,
mainly CREB, c-Jun and NF-κB (Medeiros et al., 2009). Our results
demonstrated the involvement of NO in the keratinocyte hyperpro-
liferative process; although the mechanism of this effect was not
investigated in our study, literature data suggest that this effect could
include the involvement of NF-κB.
Leukocytes are defence cells and their main function is to protect
our body during inﬂammation. The presence of polymorphonuclear
leukocytes is often correlated to evaluation of myeloperoxidase
enzymatic activity (Bradley et al., 1982) and mononuclear leukocytes
to NAG enzymatic activity. Thus, we have found that in the chronic
skin inﬂammation model NO induction by SNP application led to an
increase in polymorphonuclear migration, while a decrease of both
myeloperoxidase and NAG activity was observed with 7-NI treat-
ment. Thus, in this case, cell inﬁltration mediated by NO during the
inﬂammatory process must be due to nNOS activity. We believe that
the improvement of the keratinocyte proliferation process is caused
especially by the inhibition of NO local synthesis. Although iNOS is the
major source of NO in neutrophils and macrophages (Bogdan, 2001),
AG had no effects on cellular migration and it was shown to decrease
keratinocyte proliferation. However, 7-NI treatment seems to be
acting directly and indirectly in the inﬂammatory process, since it
reduced cell migration, consequently decreasing NO formation by
these cells, and, also, attenuating the keratinocytes hyperprolifera-
tion. Some authors reported that low NO concentration induced byL-NAME administration may decrease cytokines levels as well as
growth factors such as transforming growth factor-beta 1 (TGF-β1).
The low levels of TGF-b1 may also contribute to reduced recruitment
of inﬂammatory cells to the injury site (Amadeu and Costa, 2006).
The expression and activity of NOS isoforms seems to be cell-
speciﬁc, since these enzymes have a differential compartmentalization
in different organs (Villanueva and Giulivi, 2010). According to
Kobayashi (2010), iNOS, activated in pathological processes, produces
a large amount of NO, which may play a harmful role or an effector
function. This is common in neutrophils, and perhaps in other cells such
asmacrophages. Thus, it is clear thatNOplays a dual immunoregulatory
role in the induction and resolution of inﬂammation. A small amount of
NO can increase the production of chemokines such asMIP-2 andMCP-
1, probably via activation of NF-κB, while a large amount of NO can
eliminate it. Therefore, the levels of produced NO are of great relevance
to the effect played by NO (Kobayashi, 2010). Thus, we believe that
different effects of NO on the skin are also due to the presence of
different isoforms of NOS in each skin cell type. Thus, we suggest that
NOproduced by eNOS and nNOSwould be involved especially in edema
formation, while the NO produced by iNOS and nNOS would regulates
keratinocyte hyperproliferation and cell migration.
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